Imatinib as the first and only treatment in Europe for adult patients at significant risk of relapse following gastrointestinal stromal tumor removal

Clinical and Experimental Gastroenterology

Volumn 3, Issue 1, 2010, Pages 41-47

  Duffaud, F ^a   Salas, S ^a   Huyn, T ^a   Deville, J L ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

Adjuvant therapy; Gastrointestinal stromal tumors; GIST; Imatinib

Indexed keywords

ABELSON KINASE; CYTOCHROME P450 3A4; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR RECEPTOR;

ABDOMINAL PAIN; ADULT; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; CANCER RELAPSE; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DERMATITIS; DIARRHEA; DISEASE FREE INTERVAL; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FLATULENCE; GASTROINTESTINAL STROMAL TUMOR; HIGH RISK PATIENT; HUMAN; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SELECTION; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; RISK ASSESSMENT; TREATMENT DURATION;

EID: 77955433063     PISSN: None     EISSN: 11787023     Source Type: Book Series    
DOI: 10.2147/ceg.s7068     Document Type: Review

References (50)

1. Van der Zwan SM, De Matteo RP. Gastrointestinal stromal tumor: 5 years later. Cancer. 2005;103:1781-1788.
2. Mucciarini C, Rossi G, Bertolini F, et al. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer. 2007;7:230.
3. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gstrointestinal stromaltumors: the incidence, prevalence, clinical course, and prognostication in the preimatinibmesylate era- a population based study in western Sweden. Cancer. 2005;103:821-829.
4. Steigen SE, Eide RJ. Trends in incidence and surzvival ofmesenchymal neoplasm of the digestive tract within a defined population of northern Norway. APMIS. 2006;114:192-200.
5. Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: current diagnosis, biologic behaviour, and management. Ann Surg Oncol. 2000;7:705-712.
6. Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol. 2008;3:557-586.
7. D'Amato G, Steinert DM, McAuliffe JC, Trent JC. Update on thebiology and therapy of gastrointestinal stromal tumors. Cancer Control. 2005;12:44-56.
8. Chompret A, Kannengiesser C, Barrois M, et al. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology. 2004;126:318-321.
9. Nishida T, Hirota S, Taniguchi M, et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet. 1998;19:323-324.
10. Demetri GD, Benjamin RS, Blnacke CD, et al. NCCN Task Force. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Cancer Netw. 2007;5(Suppl 2):S1-S29.
11. DeMatteo RP, lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;213:51-58.
12. DeMatteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008;112:608-615.
13. Plaat BE, Hollema H, Molenaar WM, et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in the clinical outcome and expression of multidrug resistance proteins. J Clin Oncol. 2000;18:3211-3220.
14. Hsu KH, Yang TM, Shan YS, Lin PW. Tumor size is a major determinant of recurrence in patients with resectable gastrointestinal stromal tumor. Am J Surg. 2007;194:148-152.
15. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459-465.
16. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;29:52-68.
17. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard versus versus higher-dose imatinib mesylate for patients with unresectable gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620-625.
18. Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI 571 Glivec®, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer. 2003;39:2006-2011.
19. Verweij J, Casali PG, Zalcberg J, et al. progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial. Lancet. 2004;364:1127-1134.
20. Demetri GD, ven Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
21. Van Glabbeke MM, Owzar K, Rnakin C, et al. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta analysis base don 1,640 patients (pts). J Clin Oncol. (Meeting Abstracts) 2007;25(18 Suppl):10004.
22. Van Glabekke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors a European organisation for research and treatment of cancer-italian sarcoma group-australasian gastrointestinal trials group study. J Clin Oncol. 2005;23:5795-5804.
23. Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY, et al; for the ESMO Guidelines working Group. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment, and follow up. Ann Oncol. 2009;20 Suppl 4:64-67.
24. Judson I. Gastrointestinal stromal tumour (GIST): biology and treatment. Ann Oncol. 2002;13(Suppl 4):287-289.
25. Gold JS, DeMatteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg. 2006;244:176-184.
26. Peng B, Llyod P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44:879-894.
27. Novartis Europharm Limited. Product information (EU): Glivec® (imatinib mesylate) tablets 100 mg and 400 mg. http://www.emea. eu.int/Accessed Jan 22, 2007.
28. Asif M, Siddiqui A, Scott LJ. Imatinib. A Review of its use in the management of gastrointestinal stromal tumors. Drugs. 2007;67: 805-820.
29. Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)-expansion and update of NCCN Clinical Practice Guidelines. J Natl Compr Canc Netw. 2004;2(Suppl 1):S1-S26.
30. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing-over to a daily imatinib dose of 800 mg after progression of 400 mg. Eur J Cancer. 2005;41:1751-1757.
31. DeMatteo RP, Antonescu CR, Chadaram V, et al. Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST). 38th Annual Meeting of the ASCO. Orlando, FL 2002. J Clin Oncol. 2002(Suppl):Abstract 1610.
32. DeMatteo RP, et al 2008 GastroIntestinal Cancers Symposium Abstract 8 (2008)
33. Nilsson B, Sjolund K, Kindblom LG, Meis-Kindblom JM, Bumming P, Nilsson O. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer. 2007;96:1656-1658.
34. Blay JY, Bonvalot S, Casali PG, et al. GIST consensus meeting panellist. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol. 2005;16:566-578.
35. Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY; on behalf of the ESMO Guidelines Working Group. Gastrointestinal stromal tumors.: ESMO clinical recommendations for diagnosis, treatment, and follow-up. Ann Oncol. 2008;19(Suppl II):35-38.
36. DeMatteo RP, Owzar K, Maki R, et al. Adjuvant imatinib mesylate increases recurrence-free survival (RFS) in patients with completely resected localized primarygastrointestinale stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. J Clin Oncol. (Meeting Abstracts) 2007;25(18 Suppl):10079.
37. DeMatteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097-1104.
38. Blay JY, Le Cesne A, Ray-Coquard, Bui B, Duffaud F, et al. Prospective multicentric randomized phase III of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond one year: the French Sarcoma Group. J Clin Oncol. 2007;25:1107-1113.
39. Le Cesne A, Ray-Coquard I, Bui B, et al. Continuous versus interruption of imatinib (IM) in responding patients with advanced GIST after three years of treatment: A prospective randomized phase III trial of the French Sarcoma Group. J Clin Oncol. (Meeting Abstracts) 2007;25(18 Suppl):10005.
40. M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130:1466-1478.
41. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23:79-83.
42. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39:1411-1419.
43. Martin J, Poveda A, Llombart-Bosch A, et al. Deletions affecting codons 557-558 of the c-kit gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors. A study by the Spanish group for sarcoma research (GEIS). J Clin Oncol. 2005;23:6190-6198.
44. Miettinen M, El-Rifai W, H.L Sobin L, Lasota J, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol. 2002;33:478-483.
45. Huang HY, Li CF, Huang WW, et al. A modif ication of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome. Surgery. 2007;141: 748-756.
46. Goh BK, Chow PK, Yap WM, et al. Which is the optimal risk straficitation system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors, and proposal for a modified Armed Forces Institute of Pathology risk criteria. Ann Surg Oncol. 2008;15:2153-2163.
47. Gold J, Gonen M, Gutierez A, Broto XM, Gacia-del-Muto X, Smyrk T, et al. development and validation of a prognostic nomogram for recurrence- free survival after complete surgical resection of localised primary gastro-intestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009. 10 November. [Epub ahead of print].
48. Debiec-Richter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006;42:1093-1103.
49. Heinrich MC, Corless CL, Rankin C, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708-710.
50. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vivo sensitivity. J Clin Oncol. 2005;23:2357-2364.